| Japanese |
|---|
| Title | 111In-Antimyosin Fabを用いた心筋シンチグラフィの臨床応用 - 多施設による共同研究 - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 河合忠一*, 松森昭*, 西村恒彦**, 遠藤啓吾*** |
|---|
| Authors(kana) | |
|---|
| Organization | *京都大学医学部・第三内科, **国立循環器病センター・放射線診療部, ***京都大学医学部・核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 27 |
|---|
| Number | 12 |
|---|
| Page | 1419-1432 |
|---|
| Year/Month | 1990/12 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」全国26施設において, 111In-Antimyosin Fab (以下本剤と略す) による心筋シンチグラフィを, 心筋梗塞255例 (術後梗塞11例を含む), 心筋炎34例, 心筋症57例など計380例を対象に実施し, その臨床的有用性の評価を行った. 皮内テストで陰性を確認した後, 本剤を74MBq (2mCi) 静注し, 2日後にPlanarおよびSPECTの撮像を施行した. また, 本剤投与前後での血清中の抗マウス抗体の有無を検討した. 380例中3例に本剤投与に起因すると考えられた軽度の発熱および掻痒感を伴う皮膚発赤の自他覚症状がみられたのみで安全性は高いことが明かとなった. 心筋梗塞244例 (術後梗塞11例を除く) の検討では, 前壁・下壁・側壁などいずれの部位でも75%以上の陽性描出を認めた. 発症から8週後までの症例で77%以上に梗塞部位に一致して陽性描出を認めた. 心筋炎34例の検討では, 心筋生検で急性期所見の確認できた症例で高い検出率を呈した. 拡張型および肥大型心筋症57例の検討では心筋細胞障害の存在を示唆する可能性を示した. 本剤による心筋シンチグラフィは急性期のみならず亜急性期の心筋梗塞, 心筋炎や心筋症における心筋細胞障害検出の非侵襲的診断法として極めて有用な検査法であると考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 111In-Antimyosin Fab, myocardial infarction, myocarditis, cardiomyopathy, scintigraphy. |
|---|
| English |
|---|
| Title | 111In-Antimyosin Fab Scintigraphy in Cardiovascular Diseases : (Multicenter Clinical Trial) |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Chuichi KAWAI*, Akira MATSUMORI*, Tsunehiko NISHIMURA**, Keigo ENDO*** |
|---|
| Authors(kana) | |
|---|
| Organization | *Third Division, Department of Internal Medicine, Kyoto University, **Department of Radiology, National Cardiovascular Center, ***Department of Nuclear Medicine, Kyoto University |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 27 |
|---|
| Number | 12 |
|---|
| Page | 1419-1432 |
|---|
| Year/Month | 1990/12 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] In a multicenter study, a total of 380 patients with myocardial infarction, myocarditis and cardiomyopathy underwent 111In-Antimyosin Fab myocardial imaging. 111In-Antimyosin Fab was administered intravenously and myocardial images were obtained 48 hours later. Only 3 patients developed mild adverse effects. Human antimouse antibodies were detected in 7 patients. Positive scans in patients with myocardial infarction were seen in 92/119 (77%) within 2 weeks after the onset of myocardial infarction, in 58/71 (82%) at 3 - 4 weeks, in 20/22 (91%) at 4 - 8 weeks and 17/31 (55%) thereafter. The location of myocardial damage delineated by 111In-Antimyosin Fab imaging was concordant with the infarct location by ECG and coronary angiography. In patients with myocarditis, 111In-Antimyosin Fab uptake was positive in 7/12 (58%) within 8 weeks and 6/17 (35%) thereafter. Positive 111In-Antimyosin Fab scans were seen in 12/36 (33%) in dilated cardiomyopathy and in 17/19 (89%) in hypertrophic cardiomyopathy. Although the mechanism of persistently positive 111In-Antimyosin Fab images in the subacute to chronic stage of myocardial infarction and myocarditis remains to be clarified, 111In-Antimyosin Fab may be useful for the detection of the diseases and in evaluating the prognosis of patients with cardiomyopathy. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 111In-Antimyosin Fab, myocardial infarction, myocarditis, cardiomyopathy, scintigraphy. |
|---|